Why Now Daily.

Published

BNP and NT-proBNP Tests: Heart-Stress Markers Explained

BNP and NT-proBNP are related products released as the heart responds to wall stress. Low concentrations can make heart failure less likely in an appropriate symptomatic patient, while high values support further evaluation but do not establish the diagnosis or type. Age, kidney function, atrial rhythm, obesity…

Timeline

  1. 2022-04-01: The AHA/ACC/HFSA guideline updated recommendations for evaluating and managing heart failure.
  2. 2025-09-03: NICE updated its chronic-heart-failure guideline and quality standard.
  3. 2026-10-12: Current MedlinePlus, NICE, AHA and ACC natriuretic-peptide guidance was reviewed for this guide.

BNP and NT-proBNP are natriuretic peptides measured in blood when heart failure is being considered. The heart releases a precursor in response to wall stretch and pressure; processing produces biologically active B-type natriuretic peptide, or BNP, and the inactive N-terminal fragment, NT-proBNP. Both reflect cardiac stress, but they are different molecules with different concentrations and laboratory thresholds. A BNP value cannot be converted casually into an NT-proBNP value or compared against the other test’s cutoff. [1][3]

Their most useful role is often to change the probability that symptoms come from heart failure. In a person with breathlessness, swelling, fatigue or difficulty lying flat, a low result in the appropriate pathway can make heart failure less likely and direct attention to other causes. A high result supports cardiac evaluation but does not confirm heart failure by itself. History, examination, ECG, chest imaging, kidney tests and especially echocardiography may be needed to assess structure, pumping, filling pressures and valves. [1][2][3][4]

Thresholds depend on setting and guideline. Acute breathlessness in an emergency department is not interpreted with exactly the same pathway as gradually developing symptoms in primary care. NICE’s chronic-heart-failure pathway uses NT-proBNP below 400 ng/L in an untreated person to make heart failure less likely, 400 to 2,000 ng/L for specialist assessment and echocardiography within six weeks, and above 2,000 ng/L for referral within two weeks. Those are pathway-specific NT-proBNP referral bands, not universal BNP cutoffs or standalone diagnoses. [2]

Higher values have several possible explanations. Kidney dysfunction can reduce clearance; concentrations also tend to rise with age and may be higher with atrial fibrillation. Valve disease, other heart-muscle disease, pulmonary embolism, pulmonary hypertension, chronic lung disease, liver disease and severe systemic illness such as sepsis can elevate a natriuretic peptide. Clinicians therefore ask whether the value fits congestion and cardiac findings instead of assuming that every high result means the same disease or severity. [1][2]

A lower value is not absolute reassurance. MedlinePlus and NICE warn that obesity can suppress natriuretic-peptide concentrations, and NICE lists several heart-failure treatments that may reduce them. Timing and a person’s prior baseline also matter. If symptoms and examination strongly suggest heart failure, clinicians can continue with echocardiography or specialist review even when the result is below a usual threshold. The test modifies clinical probability; it does not overrule a concerning presentation. [1][2]

BNP and NT-proBNP do not identify ejection-fraction category. NICE states that the peptide level does not distinguish heart failure with preserved, mildly reduced or reduced ejection fraction. ACC notes that when ejection fraction is above 40 percent, confirmation requires evidence of increased filling pressures from imaging, hemodynamics or markers such as a natriuretic peptide. An echocardiogram supplies different information about chamber size, wall motion, valves and pumping, so the blood test and scan complement rather than replace one another. [2][3][4]

Serial values can help in selected patients, but a change is not a self-treatment target. Concentrations may move with fluid status, kidney function, rhythm, acute illness and therapy, and BNP and NT-proBNP can respond differently to some medicines. Compare results from the same assay and clinical setting when possible, and ask what question the clinician is using the trend to answer. Do not change a diuretic, salt or fluid intake, or another prescribed medicine solely because a portal number rose or fell. [1][2][3]

Seek urgent care for severe or rapidly worsening breathlessness, chest pain, fainting, blue or gray lips, confusion, or inability to breathe when lying down rather than waiting for routine follow-up. For a stable result, ask whether the assay was BNP or NT-proBNP, which setting-specific threshold applies, and how age, kidney function, body size, rhythm and treatment affect interpretation. The peptide is best viewed as a heart-stress signal: low values can help rule out heart failure, high values identify the need for context and often imaging, and neither result tells the whole story alone. [1][2][3][4]

Sources

  1. MedlinePlus — Natriuretic Peptide Tests (BNP, NT-proBNP)
  2. NICE — Chronic Heart Failure in Adults: Recommendations
  3. American Heart Association — Diagnosing Heart Failure
  4. American College of Cardiology — 2022 AHA/ACC/HFSA Heart Failure Guideline: Key Perspectives

Related stories